Condition

Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma (3)

Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer (2)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer (2)

Metastatic Gastric Adenocarcinoma or Cancer (2)

Locally Advanced Unresectable Gastric Adenocarcinoma Cancer (1)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer (1)

Metastatic Gastric Adenocarcinoma Cancer (1)

Overall Status

Active, not recruiting (2)

Available (1)

Phase

phase 3 (2)

Sponsor

Astellas Pharma Global Development, Inc. (3)

Collaborator

Intervention

zolbetuximab (3)

oxaliplatin (2)

placebo (2)

capecitabine (1)

fluorouracil (1)

folinic acid (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (3)

Study Type

Interventional (2)

Expanded Access (1)

metastatic gastroesophageal junction (gej) adenocarcinoma

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric

Available

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer
+3 more

zolbetuximab

Morristown, New Jersey

AMG Hematology/Oncology

Sep 15, 2023

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric

Active, not recruiting

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
+3 more

zolbetuximab
+3 more

Los Angeles, California
+164 more

Jan 16, 2023

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric

Active, not recruiting

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
+3 more

zolbetuximab
+4 more

Phoenix, Arizona
+219 more

Aug 16, 2022